Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0002064111 | Skin | SCCIS | epithelial cell development | 29/919 | 220/18723 | 1.25e-06 | 8.07e-05 | 29 |
GO:001097518 | Skin | SCCIS | regulation of neuron projection development | 44/919 | 445/18723 | 8.33e-06 | 3.03e-04 | 44 |
GO:0032496110 | Skin | SCCIS | response to lipopolysaccharide | 34/919 | 343/18723 | 8.22e-05 | 1.89e-03 | 34 |
GO:1903311111 | Skin | SCCIS | regulation of mRNA metabolic process | 30/919 | 288/18723 | 8.73e-05 | 1.99e-03 | 30 |
GO:0002237110 | Skin | SCCIS | response to molecule of bacterial origin | 35/919 | 363/18723 | 1.13e-04 | 2.41e-03 | 35 |
GO:002178211 | Skin | SCCIS | glial cell development | 16/919 | 116/18723 | 1.72e-04 | 3.35e-03 | 16 |
GO:0006417112 | Skin | SCCIS | regulation of translation | 41/919 | 468/18723 | 2.48e-04 | 4.52e-03 | 41 |
GO:004206314 | Skin | SCCIS | gliogenesis | 29/919 | 301/18723 | 4.28e-04 | 6.87e-03 | 29 |
GO:004870811 | Skin | SCCIS | astrocyte differentiation | 12/919 | 81/18723 | 5.65e-04 | 8.52e-03 | 12 |
GO:001000112 | Skin | SCCIS | glial cell differentiation | 23/919 | 225/18723 | 7.26e-04 | 1.03e-02 | 23 |
GO:004510413 | Skin | SCCIS | intermediate filament cytoskeleton organization | 9/919 | 51/18723 | 7.53e-04 | 1.03e-02 | 9 |
GO:004510313 | Skin | SCCIS | intermediate filament-based process | 9/919 | 52/18723 | 8.72e-04 | 1.14e-02 | 9 |
GO:00140021 | Skin | SCCIS | astrocyte development | 8/919 | 43/18723 | 1.02e-03 | 1.27e-02 | 8 |
GO:00329632 | Skin | SCCIS | collagen metabolic process | 13/919 | 104/18723 | 1.72e-03 | 1.87e-02 | 13 |
GO:0034250112 | Skin | SCCIS | positive regulation of cellular amide metabolic process | 17/919 | 162/18723 | 2.59e-03 | 2.48e-02 | 17 |
GO:0043488110 | Skin | SCCIS | regulation of mRNA stability | 16/919 | 158/18723 | 4.83e-03 | 3.98e-02 | 16 |
GO:00451093 | Skin | SCCIS | intermediate filament organization | 5/919 | 25/18723 | 6.59e-03 | 4.89e-02 | 5 |
GO:190331126 | Skin | cSCC | regulation of mRNA metabolic process | 162/4864 | 288/18723 | 5.90e-28 | 2.46e-25 | 162 |
GO:000641729 | Skin | cSCC | regulation of translation | 226/4864 | 468/18723 | 8.78e-26 | 2.62e-23 | 226 |
GO:0045727112 | Skin | cSCC | positive regulation of translation | 79/4864 | 136/18723 | 2.09e-15 | 1.75e-13 | 79 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0516941 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
hsa0516951 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0516924 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa05169111 | Endometrium | AEH | Epstein-Barr virus infection | 42/1197 | 202/8465 | 5.72e-03 | 3.05e-02 | 2.23e-02 | 42 |
hsa0516925 | Endometrium | EEC | Epstein-Barr virus infection | 47/1237 | 202/8465 | 6.17e-04 | 4.41e-03 | 3.29e-03 | 47 |
hsa0516934 | Endometrium | EEC | Epstein-Barr virus infection | 47/1237 | 202/8465 | 6.17e-04 | 4.41e-03 | 3.29e-03 | 47 |
hsa0516930 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa05169114 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0516914 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa0516915 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa0516931 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VIM | SNV | Missense_Mutation | | c.585N>C | p.Gln195His | p.Q195H | P08670 | protein_coding | tolerated(0.54) | possibly_damaging(0.774) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
VIM | SNV | Missense_Mutation | | c.661G>A | p.Glu221Lys | p.E221K | P08670 | protein_coding | deleterious(0.01) | possibly_damaging(0.867) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
VIM | SNV | Missense_Mutation | novel | c.406G>C | p.Glu136Gln | p.E136Q | P08670 | protein_coding | tolerated(0.28) | probably_damaging(0.954) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VIM | SNV | Missense_Mutation | | c.1349N>C | p.Arg450Thr | p.R450T | P08670 | protein_coding | deleterious(0) | possibly_damaging(0.703) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VIM | insertion | In_Frame_Ins | novel | c.577_578insGGGGCGGGGATGGCGGGGCTGTCC | p.Met193delinsArgGlyGlyAspGlyGlyAlaValLeu | p.M193delinsRGGDGGAVL | P08670 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VIM | SNV | Missense_Mutation | | c.459N>C | p.Glu153Asp | p.E153D | P08670 | protein_coding | deleterious(0.01) | possibly_damaging(0.472) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
VIM | SNV | Missense_Mutation | rs376668602 | c.1369N>A | p.Glu457Lys | p.E457K | P08670 | protein_coding | deleterious(0) | possibly_damaging(0.877) | TCGA-VS-A8QC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | paclitaxel | PD |
VIM | SNV | Missense_Mutation | rs373859810 | c.1230N>C | p.Arg410Ser | p.R410S | P08670 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VIM | SNV | Missense_Mutation | | c.628N>A | p.Val210Ile | p.V210I | P08670 | protein_coding | deleterious(0) | possibly_damaging(0.631) | TCGA-AA-A02K-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | PD |
VIM | SNV | Missense_Mutation | | c.211C>T | p.Arg71Trp | p.R71W | P08670 | protein_coding | tolerated(0.1) | probably_damaging(0.93) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |